37 completed. 37 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 37 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Enfortumab vedotin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 2 | Completed | Astellas Pharma Inc | 219 | 2017-10-08 | 2024-08-27 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2014-12-11 | 2019-12-16 |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Vinflunine, Gemcitabine, Carboplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Dr Anders Ullén | 62 | 2014-04-01 | 2019-10-08 |
| Cabozantinib for Advanced Urothelial Cancer Cabozantinib - Urothelial Carcinoma, Urethral Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 69 | 2012-09-11 | 2022-10-18 |
| A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Cisplatin, Gemcitabine, ALT-801 - Transitional Cell Carcinoma of Bladder, Urethra Cancer | Phase 1 / Phase 2 | Completed | Altor BioScience | 68 | 2011-09-06 | 2024-06-25 |
| Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Docetaxel, Ramucirumab DP, Icrucumab - Carcinoma of Urinary Tract, Urethral Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 148 | 2011-04-01 | 2019-09-09 |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer carboplatin, gemcitabine hydrochloride, vandetanib - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | Cardiff University | 82 | 2010-06-01 | 2019-05-16 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment pazopanib hydrochloride, fludeoxyglucose F 18 - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 41 | 2009-12-01 | 2013-08-12 |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) cisplatin, gemcitabine hydrochloride, sunitinib malate - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | Cardiff University | 63 | 2009-04-01 | 2018-10-26 |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer pazopanib hydrochloride - Distal Urethral Cancer, Proximal Urethral Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2008-08-01 | 2014-05-30 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
| A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer AZD4877 - Bladder Cancer, Transitional Cell Bladder Cancer | Phase 2 | Completed | AstraZeneca | 54 | 2008-05-01 | 2011-01-12 |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium cisplatin, gemcitabine hydrochloride, temsirolimus - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 1 / Phase 2 | Completed | Cardiff University | 15 | 2008-02-01 | 2018-02-06 |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride - Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2007-04-01 | 2020-10-09 |
| VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium ziv-aflibercept, pharmacological study - Adenocarcinoma of the Bladder, Distal Urethral Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2006-11-01 | 2014-10-20 |
| Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium sunitinib malate - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 78 | 2006-09-01 | 2016-01-25 |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium gemcitabine hydrochloride, pemetrexed disodium - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2004-08-10 | 2023-06-22 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium TOCOSOL Paclitaxel - Bladder Neoplasms, Ureteral Neoplasms | Phase 2 | Completed | Achieve Life Sciences | 44 | 2003-11-01 | 2009-06-04 |
Showing 20 of 37. Sign in to see all of them.
Urinary Bladder Neoplasms (34) · Ureteral Neoplasms (13) · Carcinoma, Transitional Cell (5) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Urologic Neoplasms (1)
Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Male Urogenital Diseases (37) · Neoplasms by Site (37) · Urethral Diseases (37) · Urogenital Diseases (37) · Urogenital Neoplasms (37) · Urologic Diseases (37) · Neoplasms (36) · Urologic Neoplasms (36) · Urinary Bladder Diseases (34) · Ureteral Diseases (13) · Carcinoma (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6)
Gemcitabine (15) · Cisplatin (8) · Carboplatin (5) · Paclitaxel (5) · Fluorouracil (3) · Radiotherapy (3) · Docetaxel (2) · Doxorubicin (2) · Ifosfamide (2) · Neoadjuvant Therapy (2) · Sunitinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · ALT-801 (1) · Arsenic Trioxide (1) · Biopsy (1)
National Cancer Institute (NCI) (8) · Eastern Cooperative Oncology Group (4) · SWOG Cancer Research Network (4) · Cardiff University (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (2) · Achieve Life Sciences (1) · Altor BioScience (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Dr Anders Ullén (1) · Eli Lilly and Company (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Mayo Clinic (1)
United States (26) · United Kingdom (6) · Netherlands (5) · Canada (4) · Italy (4) · Spain (4) · France (3) · Germany (3) · South Africa (3) · Belgium (2) · Denmark (2) · Israel (2) · South Korea (2) · Austria (1) · Brazil (1)
Dean F. Bajorin, MD (2) · Robert Dreicer, MD, FACP (2) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Arlene Siefker-Radtke (1) · Bruce J. Roth, MD (1) · Colin P. Dinney, MD (1) · Daniel P. Petrylak, MD (1) · David J. Vaughn, MD (1) · Dean Bajorin (1) · Evan Y Yu (1) · Gary Hudes, MD (1) · Gerwin Kaiser, MD (1)
PMID 12448661, PMID 12767086, PMID 15911238, PMID 18459175, PMID 18501081, PMID 19269798, PMID 19371909, PMID 19786668, PMID 22162575, PMID 22819172, PMID 23329066, PMID 25427282, PMID 26149529, PMID 26582660, PMID 26926681, PMID 31356140, PMID 31390274, PMID 31648851, PMID 32645282, PMID 33991512, PMID 35168844
U10CA032102 (4), U10CA031946 (2), N01CM00038 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA015704 (1), P30CA016672 (1), P30CA093373 (1), U01CA154967 (1), U10CA021115 (1), U10CA045809 (1)